---
title: "SELECT: Semaglutide Phase 3 Results | Primara Labs"
url: https://www.primaralabs.com/research/trials/select
source: Primara Labs, markdown mirror of the HTML page
---

# SELECT

In SELECT, a phase 3 trial of semaglutide in patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes (n=17,604), the primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90) (Lincoff AM et al. N Engl J Med 2023 (SELECT)).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Updated 24 September 2026

## Results

The primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90).

## Side effects reported

In SELECT, discontinuation because of adverse events was 16.6% on semaglutide 2.4 mg, against 8.2% on placebo.

| Event | Semaglutide 2.4 mg | Placebo |
| --- | --- | --- |
| Discontinuation for adverse events | 16.6% | 8.2% |

Design

## Trial design and sources

Compound

Semaglutide

Phase

3

Population

Patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes

Participants randomised

17,604

Duration

Not published

Primary endpoint

Composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (time to first event)

Estimand

Not stated in the source read

Read out

11 November 2023

Event-driven cardiovascular outcomes trial; mean follow-up 39.8 months. The abstract states no body-weight figure.

-   Lincoff AM et al. N Engl J Med 2023 (SELECT) [open](https://doi.org/10.1056/NEJMoa2307563) · checked 23 September 2026
-   ClinicalTrials.gov NCT03574597 [open](https://clinicaltrials.gov/study/NCT03574597) · checked 23 September 2026
-   Registry: NCT03574597

Questions

## SELECT, answered

### What did SELECT find?

In SELECT, a phase 3 trial of semaglutide in patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes (n=17,604), the primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90) (Lincoff AM et al. N Engl J Med 2023 (SELECT)).

### What side effects were reported in SELECT?

In SELECT, discontinuation because of adverse events was 16.6% on semaglutide 2.4 mg, against 8.2% on placebo.

Related

## More on semaglutide

-   [STEP 1](https://www.primaralabs.com/research/trials/step-1)
-   [STEP 2](https://www.primaralabs.com/research/trials/step-2)
-   [STEP 3](https://www.primaralabs.com/research/trials/step-3)
-   [STEP 4](https://www.primaralabs.com/research/trials/step-4)
-   [STEP 5](https://www.primaralabs.com/research/trials/step-5)
-   [STEP 8](https://www.primaralabs.com/research/trials/step-8)
-   [SURMOUNT-5](https://www.primaralabs.com/research/trials/surmount-5)
-   [Evidence Map: Semaglutide](https://www.primaralabs.com/research/evidence#semaglutide)
-   [Semaglutide 15mg](https://www.primaralabs.com/marketplace/semaglutide-15mg)